COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04535986
Recruitment Status : Recruiting
First Posted : September 2, 2020
Last Update Posted : January 14, 2021
Sponsor:
Collaborator:
Iqvia Pty Ltd
Information provided by (Responsible Party):
Verona Pharma plc

Brief Summary:
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Ensifentrine Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Actual Study Start Date : September 29, 2020
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : August 2022

Arm Intervention/treatment
Experimental: Arm 1
Ensifentrine Nebulized Suspension; 3 mg BID
Drug: Ensifentrine

• Dosage Formulation: Ensifentrine Nebulizer suspension

  • Dosage 3mg
  • Frequency: Twice Daily
  • Study to randomize 800 patients in total
  • Subjects randomized to the 24-week subset will enroll 400 patients (1:1 ensifentrine (3 mg): placebo)
  • Subjects randomized to the 48-week subset will enroll approximately 400 patients randomized 3:1 ensifentrine (3 mg): placebo.

Placebo Comparator: Arm 2
Placebo Nebulized BID
Drug: Placebo

• Dosage Formulation: Ensifentrine Nebulizer suspension

  • Dosage 3mg
  • Frequency: Twice Daily
  • Study to randomize 800 patients in total
  • Subjects randomized to the 24-week subset will enroll 400 patients (1:1 ensifentrine (3 mg): placebo)
  • Subjects randomized to the 48-week subset will enroll approximately 400 patients randomized 3:1 ensifentrine (3 mg): placebo.




Primary Outcome Measures :
  1. Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h [ Time Frame: 12 weeks ]
    Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h


Secondary Outcome Measures :
  1. Average FEV1 AUC0-4h post-dose at Week 12 [ Time Frame: 12 weeks ]
    Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12

  2. Peak FEV1 over 4 hours post dose at Week 12 [ Time Frame: 12 weeks ]
    Change from baseline in Peak FEV1 over 4 hours post dose at Week 12

  3. Weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24 [ Time Frame: 24 weeks ]
    Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24

  4. St. George's Respiratory Questionnaire (SGRQ) total score at Week 24 [ Time Frame: 24 weeks ]
    Change from baseline of SGRQ total score at Week 24

  5. Morning trough FEV1 at Week 12 [ Time Frame: 12 weeks ]
    Change from baseline of Morning trough FEV1 at Week 12

  6. St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: 24 weeks ]
    The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.

  7. Rescue medication use at Week 24 [ Time Frame: 24 weeks ]
    Change from baseline of Rescue medication use at Week 24

  8. Transitional Dyspnea Index (TDI) at Week 24 [ Time Frame: 24 weeks ]
    Transitional Dyspnea Index (TDI) at Week 24

  9. Evening trough FEV1 at Week 12 [ Time Frame: 12 weeks ]
    Change from baseline Evening trough FEV1 at Week 12

  10. Peak FEV1 at Week 6 and Week 24 [ Time Frame: 6 and 24 weeks ]
    Change from baseline Peak FEV1

  11. Morning trough FEV1 at Week 6 and Week 24 [ Time Frame: 6 and 24 weeks ]
    Change from baseline morning trough FEV1

  12. Evening trough FEV1 at Week 6 and Week 24 [ Time Frame: 6 and 24 weeks ]
    Change from baseline evening trough FEV1

  13. FEV1 AUC0-4h at Week 6 and Week 24 [ Time Frame: 6 and 24 weeks ]
    Change from baseline FEV1 AUC0-4h

  14. Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12 [ Time Frame: 6 and 12 weeks ]
    Change from baseline E-RS Total Score

  15. St. George's Respiratory Questionnaire (SGRQ) responder analysis at Week 6 and Week 12 [ Time Frame: 6 and 12 weeks ]
    Change from baseline SGRQ responder analysis

  16. TDI at Week 6 and Week 12 [ Time Frame: 6 and 12 Weeks ]
    Change from baseline TDI

  17. St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12 [ Time Frame: 6 Weeks and 12 weeks ]
    Change from baseline of SGRQ total score at Weeks 6 and 12

  18. Rescue medication use at Weeks 6 and 12 [ Time Frame: 12 weeks ]
    Change from baseline of Rescue medication use at Weeks 6 and 12



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Informed Consent

  1. Capable of giving informed consent indicating that they understand the purpose of the study and study procedures and agree to comply with the requirements and restrictions listed in the informed consent form (ICF).

    Age and Sex

  2. Age: Patient must be 40 to 80 years of age inclusive, at the time of Screening.
  3. Sex:

    • Males are eligible to participate if they agree to use contraception as described in the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication.
    • Females are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions apply:

      1. Not a woman of childbearing potential (WOCBP) as defined in Or
      2. A WOCBP who agrees to follow the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication.

    Smoking History

  4. Smoking History: Current or former cigarette smokers with a history of cigarette smoking ≥10 pack years at Screening (Visit 0) [number of pack years = (number of cigarettes per day / 20) × number of years smoked (eg, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 0. Smoking cessation programs are permitted during the study.

    COPD Diagnosis, Symptoms, Severity and Maintenance Therapy

  5. COPD Diagnosis: Patients with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD.
  6. COPD Symptoms: A score of ≥2 on the Modified Medical Research Council (mMRC) Dyspnea Scale.
  7. COPD Severity:

    1. Pre- and Post-albuterol/salbutamol FEV1/FVC ratio of <0.70.
    2. Post-albuterol/salbutamol FEV1 ≥30 % and ≤70% of predicted normal calculated using the National Health and Nutrition Examination Survey III.
  8. Maintenance Therapy: Patients on no maintenance/background therapy or patients on stable maintenance LAMA or LABA therapy are eligible. Patients taking maintenance LAMA or LABA therapy must demonstrate stable use of the maintenance LAMA or LABA therapy for at least 3 months prior to Screening and agree to continue use for the duration of the study. Background maintenance LAMA or LABA bronchodilator therapy will be capped at 50% of patients.

    Other Requirements for Inclusion

  9. Capable of withholding SABAs for 4 hours prior to initiation of any spirometry. Patients in the maintenance LAMA or LABA therapy stratum must be capable of withholding Twice-Daily maintenance LAMA or LABA for 24 hours and Once-Daily maintenance LAMA or LABA for 48 hours prior to initiation of any spirometry.
  10. Capable of using the study nebulizer correctly and complying with all study restrictions and procedures.
  11. Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines.

Inclusion Criteria at Randomization (RPL554-CO-301)

  1. Symptoms of COPD: A score of ≥2 on the mMRC Dyspnea Scale.
  2. Completion of the e-Diary at least 5 of the last 7 days of the Run-in period.

Exclusion Criteria:

Current Condition or Medical History

  1. History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
  2. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the 12 weeks prior to Screening and/or a positive COVID-19 test result indicating an active infection at Screening. Patients with COVID-19 antibodies from a previous exposure with no active infection are not excluded.
  3. COPD exacerbation requiring oral or parenteral steroids within 3 months of Screening.
  4. Previous lung resection or lung reduction surgery within 1-year of Screening.
  5. Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours per day. As needed oxygen use (≤12 hours per day) is not exclusionary.
  6. Pulmonary rehabilitation, unless such treatment has been in a stable maintenance phase for 4 weeks prior to Visit 1 and remains stable during the study.
  7. Lower respiratory tract infection within 6 weeks of Screening.
  8. Other respiratory disorders including, but not limited to, a current diagnosis of asthma, active tuberculosis, lung cancer, sarcoidosis, lung fibrosis, interstitial lung diseases, unstable sleep apnea, known alpha-1 antitrypsin deficiency, core pulmonale, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary diseases.
  9. Major surgery (requiring general anesthesia) in the 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study.
  10. Historical or current evidence of clinically significant cardiovascular disease defined as any disease that in the opinion of the Investigator would put the safety of the patient at risk through participation or which could affect the efficacy or safety analysis if the disease/condition were to exacerbate during the study, including, but not limited to:

    • Myocardial infarction or unstable angina within 6 months prior to Screening.
    • Unstable or life-threatening cardiac arrhythmia requiring intervention within 3 months prior to Screening.
    • Diagnosis of New York Heart Association Class III and Class IV heart failure.
  11. Chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the Investigator believes are clinically significant.
  12. Unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).
  13. History of or current malignancy of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin.
  14. Findings on physical examination that an investigator considers to be clinically significant at Screening.

    Prior/Concomitant Therapy

  15. Use of prohibited medications within the time intervals.

    History or Suspicion of Drug or Alcohol Abuse

  16. Current or history of past drug or alcohol abuse within the past 5 years.

    Laboratory and Other Diagnostic Parameters

  17. Glomerular Filtration Rate (eGFR) <30 mL/min. The Chronic Kidney Disease Epidemiology Collaboration Creatinine (2009) calculation will be used (Levey, 2009).
  18. Alanine aminotransferase (ALT) ≥ 2 x upper limit of normal (ULN), alkaline phosphatase and/or bilirubin > 1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  19. Hepatitis B antibody:

    • Positive findings for both Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (anti-HBc) are excluded, as this indicates acute or chronic infection.
    • Negative findings for HBsAg and Hepatitis B surface antibody (anti-HBs) but positive findings for anti-HBc are excluded as this may indicate current or resolving infection.
    • Positive findings for anti-HBc and anti-HBs but negative findings for HBsAg are not excluded, as this indicates immunity due to natural infection.
    • Positive findings for anti-HBs but negative findings for HBsAg and anti-HBc are not excluded, as this indicates immunity due to hepatitis B vaccination.
  20. Hepatitis C antibody positive.
  21. Any other abnormal hematology, biochemistry, or viral serology deemed by an investigator to be clinically significantly abnormal. Abnormal chemistry and/or hematology may be repeated during Screening.
  22. Chest X-ray (CXR; posterior-anterior) at Screening, or in the 12 months prior to Screening with clinically significant abnormalities not attributable to COPD. If a CXR within the past 12 months is not available but a computerized tomography (CT) scan within the same time period is available, the CT scan may be reviewed in place of a CXR. For subjects in Germany, if a CXR or CT scan is not available in the 12 months prior to Screening, the subject is not eligible for the study.
  23. Electrocardiogram (ECG) finding that is significantly abnormal on the 12-lead ECG obtained at Screening.

    Other Exclusions

  24. Use of an experimental drug within 30 days or 5 half-lives of Screening, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical study within 30 days prior to Screening.
  25. Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical study within 30 days prior to Screening.
  26. Intolerance or hypersensitivity to albuterol/salbutamol or ensifentrine (RPL554) or any of its excipients/components.
  27. Prior receipt of blinded study medication in an ensifentrine (RPL554) study.
  28. Affiliation with the investigator site, including an Investigator, Sub-Investigator, study coordinator, study nurse, other employee of participating investigator or study site or a family member of the aforementioned.
  29. Inability to read, understand, and/or complete questionnaires (in the opinion of the Investigator).
  30. A disclosed history or one known to the Investigator of significant non-compliance in previous investigational studies or with prescribed medications.
  31. Any other reason that the Investigator considers makes the patient unsuitable to participate.

Exclusion Criteria at Randomization (RPL554-CO-301)

  1. COPD exacerbation or lower respiratory tract infection between Screening and Randomization (defined as use of any additional treatment other than current treatment and rescue medication and/or emergency department or hospital visit). Patients with a severe COPD exacerbation that requires hospitalization may not be rescreened.
  2. Positive COVID-19 result at Screening or between Screening and Randomization.
  3. Prohibited medication use between Screening Visit 0 and Visit 1.
  4. Significantly abnormal ECG finding on the 12-lead ECG obtained at Screening as assessed by the investigator or site medical doctor/medically qualified person or on the pre-dose (prior to randomization) ECG obtained at Visit 1.

    In the event that the central ECG reviewer discovers a significant ECG abnormality on the Visit 1 ECG, the patient will be discontinued.

  5. Did not meet one or more of the Inclusion Criteria or met one or more of the Exclusion Criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04535986


Contacts
Layout table for location contacts
Contact: Nancy Herje 646-951-0961 nancy.herje@veronapharma.com

Locations
Layout table for location information
United States, California
Beach Physicians Medical Group Recruiting
Huntington Beach, California, United States, 92647
Contact: Bassil Aish, MD    714-848-1655    bassilaish@aol.com   
Principal Investigator: Bassil Aish, MD         
United States, Florida
St. Francis Medical Institute Recruiting
Clearwater, Florida, United States, 33765
Contact: Francis Averill, MD    727-210-4606    faverillresearch@stfrancismed.com   
Principal Investigator: Francis Averill, MD         
Global Research Solutions Corp Recruiting
Miami, Florida, United States, 33144
Contact: Natalia Hegedosh, MD    954-634-7047    nhegedoshmd@globalresearchus.com   
Principal Investigator: Natalia Hegedosh, MD         
Phoenix Medical Research Recruiting
Miami, Florida, United States, 33165
Contact: Jose Birriel, MD    608-848-8900    josebirriel@researchphoenixmedical.com   
Principal Investigator: Jose Birriel, MD         
Precision Clinical Research Recruiting
Sunrise, Florida, United States, 33351
Contact: Jason Haffizulla, MD    954-915-9991    jhaffizulla@pcrflorida.com   
Principal Investigator: Jason Haffizulla, MD         
United States, Georgia
iResearch Atlanta, LLC Recruiting
Decatur, Georgia, United States, 30030
Contact: Kimball Johnson, MD    404-537-1281    drjohnson@iresearchatlanta.com   
Principal Investigator: Kimball Johnson, MD         
United States, Michigan
Pulmonary Research Institute of SE Michigan Recruiting
Farmington Hills, Michigan, United States, 48336
Contact: Gary Ferguson, MD    248-478-6561    garytferguson@msn.com   
Principal Investigator: Gary Ferguson         
United States, Missouri
The Clinical Research Center, LLC Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Jeffrey Tillinghast, MD    314-514-8509    j.tillinghast@clinicalresearchcenter.com   
Principal Investigator: Jeffrey Tillinghast, MD         
United States, Nevada
Sierra Clinical Research Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Naresh Singh, MD    702-384-5101    singh@sieraclinicalresearch.com   
Principal Investigator: Naresh Singh, MD         
United States, South Carolina
Medtrial Recruiting
Columbia, South Carolina, United States, 29204
Contact: Carl Mitchell, MD    803-254-4295    cmitchellmd@medtrialsc.com   
Principal Investigator: Carl Mitchell, MD         
United States, Texas
West Houston Clinical Research Services Recruiting
Houston, Texas, United States, 77055
Contact: Oscar DeValle, MD    281-738-2642    odevalle@whcrs.com   
Principal Investigator: Oscar DeValle, MD         
United States, Virginia
TPMG Clinical Research Williamsburg Recruiting
Williamsburg, Virginia, United States, 23188
Contact: Vijay Subramaniam, MD    757-707-3503    vijay-research@tpmgpc.com   
Principal Investigator: Vijay Subramaniam, MD         
Sponsors and Collaborators
Verona Pharma plc
Iqvia Pty Ltd
Layout table for additonal information
Responsible Party: Verona Pharma plc
ClinicalTrials.gov Identifier: NCT04535986    
Other Study ID Numbers: RPL554-CO-301
First Posted: September 2, 2020    Key Record Dates
Last Update Posted: January 14, 2021
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Verona Pharma plc:
COPD
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases